-
Otsuka and Lundbeck Win EU Approval for Rxulti in Adolescent Schizophrenia
•
Japan-based Otsuka Pharmaceutical Co., Ltd and its Danish partner Lundbeck A/S (OTCMKTS: HLUBF) jointly announced receiving marketing approval from the European Commission (EC) for Rxulti (brexpiprazole). The atypical oral antipsychotic can now be used to treat schizophrenia in adolescents aged 13 years and older in the European Union (EU). Background…
-
Lundbeck’s Amlenetug Receives Orphan Drug Designation in Japan for Multiple System Atrophy
•
Denmark-based pharmaceutical company Lundbeck A/S (OTCMKTS: HLUBF) announced receiving Orphan Drug Designation (ODD) from Japan’s Ministry of Health, Labor, and Welfare (MHLW) for its investigational drug amlenetug. This designation positions amlenetug as a promising new treatment option for patients with multiple system atrophy (MSA), a rare and progressive neurodegenerative disorder.…
-
Lundbeck’s Amlenetug Receives FDA Fast Track for Multiple System Atrophy
•
Denmark-based pharma company Lundbeck A/S (VIE: LUNB) has announced that it has received Fast Track Designation (FTD) from the US Food and Drug Administration (FDA) for its investigational drug amlenetug. The drug is expected to provide a new treatment option for patients with multiple system atrophy (MSA). Drug DetailsAmlenetug is…
-
Danish Pharma H. Lundbeck A/S Sees Strong Q3 and Q1-Q3 2024 Financial Results
•
Denmark-based pharmaceutical company H. Lundbeck A/S (OTCMKTS: HLBBF) has revealed its financial results for the third quarter and the first three quarters of 2024. For the three-month period, revenues increased by 18% year-on-year (YOY) in constant currency terms to DKK 5.722 billion (USD 805 million). Over the nine-month period, sales…
-
Lundbeck’s Vyepti Migraine Treatment Available at Sun Yat-sen Memorial Hospital Through Greater Bay Area Policy
•
Vyepti (eptinezumab), a migraine treatment developed by Denmark-based biopharmaceutical company H. Lundbeck A/S (OTCMKTS: HLBBF), has been introduced at Sun Yat-sen Memorial Hospital, Sun Yat-sen University, facilitated by the “Hong Kong-Macau Drug and Device Access” policy. This policy, part of the broader Greater Bay Area initiative, enables patients to access…
-
Lundbeck Secures Rights to Bexicaserin with Acquisition of Longboard Pharmaceuticals
•
Lundbeck A/S (VIE: LUNA), a Danish pharmaceutical company, has announced its intention to acquire U.S.-based Longboard Pharmaceuticals, Inc. (NASDAQ: LBPH) in a deal valued at USD 60.00 per share in cash. The transaction, on a fully diluted basis, is worth USD 2.6 billion in equity terms and USD 2.5 billion…
-
Lundbeck A/S Reports 7% YOY Revenue Increase in Q3 2023 and 9% Growth for the First Three Quarters
•
Denmark-based biopharmaceutical company H. Lundbeck A/S (CPH: HLUN-A) has announced its financial results for the third quarter and the first three quarters of 2023. The company reported a 7% year-on-year (YOY) increase in revenues in constant currency terms for the three-month period, reaching DKK 4.952 billion (USD 709 million). For…
-
Lundbeck A/S Reports 10% H1 2023 Revenue Increase with Record-Breaking Sales
•
Denmark-based biopharmaceutical company H. Lundbeck A/S (OTCMKTS: HLBBF) has released its financial report for the H1 2023 period, reporting a 10% year-on-year (YOY) increase in sales revenues in constant exchange rate terms, reaching DKK 10 billion (USD 1.45 billion) over the six-month period. CEO Deborah Dunsire celebrated the “excellent performance,”…
-
Lundbeck A/S Reports Record Quarterly Revenue in Q1 2023 with 11% YOY Increase
•
Denmark-based pharmaceutical company Lundbeck A/S (OTCMKTS: HLUBF) has released its financial report for the first quarter of 2023, highlighting an 11% year-on-year (YOY) increase in global sales revenues in constant exchange rate terms, reaching DKK 5.044 billion (USD 731.2 million). This figure marks the highest quarterly revenue in the company’s…
-
Neuro3 Therapeutics Secures Exclusive License Deal with Lundbeck for KCNQ2 Activator Programs
•
Neuro3 Therapeutics (Neuro3), a biotechnology company specializing in central nervous system (CNS) diseases with operations in Suzhou, China, and the US, has announced the signing of an exclusive license and option agreement with Denmark-based Lundbeck (OTCMKTS: HLUBF). This deal grants Neuro3 a global license to the intellectual property encompassing two…
-
Lundbeck’s Eptinezumab Launches in Boao Lecheng for Migraine Treatment
•
Lundbeck’s (FRA: LDBB) Eptinezumab has been launched in the Boao Lecheng International Medical Tourism Zone, marking it as the first innovative drug available in the region for migraine treatment. This milestone was announced on November 10, 2022, at a joint press conference held by the Hainan Boao Lecheng International Medical…
-
Lundbeck Initiates TALISMAN Study on Multiple System Atrophy in China and EU
•
Danish-based Lundbeck (OTCMKTS: HLUBF) has announced plans to initiate a global investigational study on multiple system atrophy (MSA), named TALISMAN. The trial will be conducted at sites in China and the European Union, marking a significant step in understanding and addressing this rare neurodegenerative disease. Disease BackgroundMSA is a rare,…
